| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-09-20 | Bluebird bio (USA - MA) | member of the board of directors | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-09-20 | Glythera (UK) Iontas (UK) | antibody drug conjugates (ADC) for difficult-to-treat cancers | difficult-to-treat cancers. | development - collaboration | Cancer - Oncology | Development agreement |
| 2017-09-20 | XBiotech (USA - TX) Cedars-Sinai Medical Center (USA - CA) | MABp1 (bermekimab) | patients with advanced pancreatic adenocarcinoma and cachexia | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-09-18 | Immunocore (UK) Bill and Melinda Gates Foundation (USA) | ImmTAV (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB (Immune mobilising monoclonal TCRs Against Bacteria) therapeutics | HIV infection, tuberculosis | development | Infectious diseases | Development agreement |
| 2017-09-18 | Brammer Bio (USA - MA) | expansion of Alachua site | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-09-17 | Merck&Co (USA - NJ) Zymeworks (Canada) | bispecific antibody therapeutic candidates generated through use of the Azymetric™ platform | development - licensing - commercialisation | undisclosed | Milestone | |
| 2017-09-14 | Daiichi Sankyo (Japan) The University of Texas MD Anderson Cancer Center (USA - TX) | quizartinib, DS-3032, DS-3201, and PLX51107 | acute myeloid leukemia (AML) | development | Cancer - Oncology | Development agreement |
| 2017-09-13 | Onxeo (France) Monopar Therapeutics (USA - IL) | Validive® (clonidine mucoadhesive buccal tablet) | severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer | licensing | Cancer - Oncology | Licensing agreement |
| 2017-09-13 | Eyevensys (France) | pre-clinical director | nomination | Rare diseases - Genetic diseases - Ophtalmological diseases | Nomination | |
| 2017-09-12 | Alexion Pharmaceuticals (USA - CT) | restructuring | Rare diseases - Genetic diseases | Restructuring | ||
| 2017-09-12 | TiGenix (Belgium) | head of medical department (US), director | nomination | Autoimmune diseases – Inflammatory diseases - Cardiovascular diseases | Nomination | |
| 2017-09-12 | Basilea Pharmaceutica (Switzerland) Cardiome Pharma (Canada) | Zevtera®/Mabelio® (ceftobiprole) | severe community-acquired and hospital-acquired pneumonia | distribution - commercialisation | Infectious diseases | Distribution agreement |
| 2017-09-12 | ProQR Therapeutics (The Netherlands) Amylon Therapeutics (The Netherlands) | therapeutics for beta amyloid related disorders | beta amyloid related disorders | establishment of a new subsidiary in the EU | CNS diseases - Neurological diseases - Neurodegenerative diseases | Establishment of a new subsidiary in the EU |
| 2017-09-12 | Lysogene (France) | clinical advisory board | nominatin | Rare diseases - Genetic diseases | Nomination | |
| 2017-09-11 | Teva Pharmaceutical (Israel) | president and chief executive officer | nomination | Nomination | ||
| 2017-09-11 | Allergy Therapeutics (UK) | clinical director, head of clinical science, senior pharmaceutical physician | nomination | Allergic diseases | Nomination | |
| 2017-09-11 | Synpromics (UK) | new facility at the Roslin Innovation Centre | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-09-11 | Amphivena Therapeutics (USA - CA) | nomination | Cancer - Oncology | Nomination | ||
| 2017-09-11 | Iovance Biotherapeutics (USA - CA) TrakCel (USA - NJ) | scheduling and logistics tool that automates the supply chain for adoptive cell therapy products that utilize tumor-infiltrating lymphocyte (TIL) technology. | collaboration | Cancer - Oncology - Technology - Services | Collaboration agreement | |
| 2017-09-07 | Adaptimmune (UK) GSK (UK) | NY-ESO SPEAR T-cell therapy program including GSK3377794 | synovial sarcoma, myxoid round cell liposarcoma | licensing | Cancer - Oncology | Exercise of an option agreement |
